Radio-pharmaceutical for patient care.
Ended Awarded Last action
- Contract number
- HT009026FG0210049
- Awardee
-
Sofie CO. UEI JV1AHJHGUGG3
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $21,863
Award facts
- Contract value 100% obligated
- $21,862.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6506 Blood And Blood Products
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Sterling, VA, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency awarded Sofie CO., doing business as IBA Molecular, a Blanket Purchase Agreement (BPA) call valued at $21,862.80 for radio-pharmaceutical supplies to support patient care at military treatment facilities. The contract, awarded February 4, 2026, with a completion date of September 30, 2026, is structured as a firm fixed-price procurement without set-aside designation. Performance will be executed in Sterling, Virginia, where Sofie CO. maintains its headquarters as a specialized supplier of molecular diagnostics and therapeutic radiopharmaceuticals, including positron emission tomography (PET) imaging agents used for oncology and neurological applications.
This task order is issued under a larger $6.5 million master BPA that the Defense Health Agency established with Sofie CO. for pharmaceutical supplies and radiopharmaceuticals, valid through February 2029. Sofie CO. is a well-established federal healthcare vendor with extensive experience supplying critical radiopharmaceuticals to the Department of Veterans Affairs, Defense Health Agency, and National Institutes of Health. The company maintains compliance with U.S. Nuclear Regulatory Commission and Food and Drug Administration requirements and operates a diversified product portfolio including PYLARIFY (piflufolastat F-18) for prostate cancer detection, NEURACEQ (florbetaben F-18) for Alzheimer's disease imaging, and various gallium-68 and fluorodeoxyglucose radiopharmaceuticals supporting diagnostic imaging across federal medical treatment facilities.
Quick answers
Who was awarded contract HT009026FG0210049?
HT009026FG0210049 was awarded to Sofie CO. by Defense Health Agency (Department of Defense) on February 4, 2026.
How much is contract HT009026FG0210049 worth?
The government has obligated $21,863 on HT009026FG0210049.
Is contract HT009026FG0210049 an order under another contract?
Yes. HT009026FG0210049 is a BPA call under HT001424A0002, a blanket purchase agreement.
Was contract HT009026FG0210049 competed?
The extent of competition for HT009026FG0210049 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award